The clinical progress in the CoMpass trial is a positive development, but the widening net loss raises concerns about sustainability. Investors should monitor the mid-2026 enrollment completion and mid-2026 NMIBC data readouts as key catalysts. The extended cash runway reduces near-term dilution risk.
Price Chart
Executive Summary
Aura Biosciences reported Q4 and full-year 2025 financial results, highlighting accelerated enrollment in its Phase 3 CoMpass trial for early choroidal melanoma with topline data expected in 2H 2027. The company has $144.2 million in cash, sufficient to fund operations into Q1 2027. Net loss increased to $106.2 million in 2025 from $86.9 million in 2024, primarily due to higher R&D expenses.
Key Financial Metrics
Key Facts
- Completed enrollment in Phase 3 CoMpass trial now expected by mid-2026, with topline data anticipated in second half of 2027
- Initial 3-month clinical data from Phase 1b/2 NMIBC trial expected mid-2026
- New formulation of bel-sar achieved 12-month stability, expanding potential in non-ocular solid tumors
- Cash and marketable securities totaled $144.2 million as of December 31, 2025
- R&D expenses increased to $90.3 million in 2025 from $73.3 million in 2024
- Net loss widened to $106.2 million in 2025 from $86.9 million in 2024
- Cash runway extends into Q1 2027
Financial Impact
Net loss increased by $19.3 million year-over-year, driven by higher R&D spending. Cash position grew to $144.2 million despite increased burn.
Risk Factors
- Clinical trial timelines could slip despite current enrollment momentum
- Increased R&D spend may pressure cash runway if fundraising is delayed
- No efficacy data yet reported; future results may not meet expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264473 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $6.45 $6.56 | ▲ +1.71% | ▲ +2.27% | $6.30 (−2.33%) |
Aug 21, 2026 9w ago | EFFECT | $7.80 $6.36 | ▲ +18.46% | ▲ +17.94% | $6.30 (+19.23%) |
Aug 11, 2026 11w ago | 8-K | $8.04 $7.20 | ▲ +10.45% | ▲ +9.39% | $6.30 (+21.64%) |
Aug 11, 2026 11w ago | Press Release | $8.04 $7.20 | ▲ +10.45% | ▲ +9.39% | $6.30 (+21.64%) |
Jul 8, 2026 15w ago | 8-K | $7.25 $7.18 | ▼ −0.97% | ▼ −4.24% | $6.30 (−13.10%) |
May 19, 2026 22w ago | Press Release | $7.47 $6.34 | ▼ −15.13% | ▼ −15.87% | $6.30 (−15.66%) |
May 5, 2026 24w ago | 8-K | $8.29 $6.88 | ▲ +17.01% | ▲ +19.79% | $6.30 (+24.00%) |
May 5, 2026 24w ago | Press Release | $8.29 $6.88 | ▲ +17.01% | ▲ +19.79% | $6.30 (+24.00%) |
May 4, 2026 25w ago | 8-K | $8.90 $6.90 | ▼ −22.47% | ▼ −27.43% | $6.30 (−29.21%) |
May 4, 2026 25w ago | Press Release | $8.35 $7.19 | ▲ +13.89% | ▲ +19.54% | $6.30 (+24.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers